{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T03:10:09Z","timestamp":1751598609428,"version":"3.41.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01837-0","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:38:16Z","timestamp":1751596696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer\u2013the EXUROC prostate study, a clinical trial protocol"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8002-0197","authenticated-orcid":false,"given":"Katrine","family":"\u00d8rum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2928-9218","authenticated-orcid":false,"given":"Dag R.","family":"Stormoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-174X","authenticated-orcid":false,"given":"Jakob","family":"Lauritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-5623","authenticated-orcid":false,"given":"Mikkel","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-7111","authenticated-orcid":false,"given":"Marja","family":"J\u00e4\u00e4ttel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-5372","authenticated-orcid":false,"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"1837_CR1","unstructured":"GLOBOCAN."},{"issue":"9","key":"1837_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ejca.2013.09.002","volume":"51","author":"M Arnold","year":"2015","unstructured":"Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer observatory. Eur J Cancer. 2015;51(9):1164\u201387.","journal-title":"Eur J Cancer"},{"key":"1837_CR3","unstructured":"https:\/\/d56bochluxqnz.cloudfront.net\/documents\/pocket-guidelines\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Pocket-on-Prostate-Cancer-2024_2024-04-16-125527_rzmb.pdf. EAU Guidelines 2024. 2025."},{"key":"1837_CR4","doi-asserted-by":"publisher","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. 2023 [cited 2024 Jun 11]; Available from: https:\/\/doi.org\/10.1038\/s41391-023-00725-8","DOI":"10.1038\/s41391-023-00725-8"},{"key":"1837_CR5","doi-asserted-by":"publisher","unstructured":"Khoshkar Y, Westerberg M, Adolfsson J, Bill-Axelson A, Olsson H, Eklund M et al. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort. 2021 [cited 2024 Jun 11]; Available from: https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/bco2.116","DOI":"10.1002\/bco2.116"},{"key":"1837_CR6","doi-asserted-by":"publisher","unstructured":"Van Der Horst G, Van De Merbel AF, Ruigrok E, Van Der Mark MH, Ploeg E, Appelman L et al. Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. 2020 [cited 2024 Jun 11]; Available from: https:\/\/febs.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/1878-0261.12793","DOI":"10.1002\/1878-0261.12793"},{"issue":"11","key":"1837_CR7","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3390\/cancers15112972","volume":"15","author":"I Ioakeim-Skoufa","year":"2023","unstructured":"Ioakeim-Skoufa I, Tobajas-Ramos N, Menditto E, Aza-Pascual-Salcedo M, Gimeno-Miguel A, Orlando V, et al. Drug repurposing in oncology: A systematic review of randomized controlled clinical trials. Cancers (Basel). 2023;15(11):2972.","journal-title":"Cancers (Basel)"},{"key":"1837_CR8","doi-asserted-by":"crossref","unstructured":"Fennelly C, Amaravadi RK. Lysosomal Biology in Cancer. 2017.","DOI":"10.1007\/978-1-4939-6934-0_19"},{"key":"1837_CR9","doi-asserted-by":"publisher","unstructured":"Levy JMM, Towers CG, Thorburn A. Target Autophagy Cancer. Nature Reviews Cancer. 2017;17(9):528\u2013542. https:\/\/doi.org\/10.1038\/nrc.2017.53","DOI":"10.1038\/nrc.2017.53"},{"key":"1837_CR10","doi-asserted-by":"crossref","unstructured":"H\u00f8yer-Hansen M, J\u00e4\u00e4ttel\u00e4 M, Autophagy. An emerging target for cancer therapy. Autophagy. 2008 [cited 2024 Jun 12];4(5):574\u201380. Available from: https:\/\/www.tandfonline.com\/action\/journalInformation?journalCode=kaup20","DOI":"10.4161\/auto.5921"},{"key":"1837_CR11","doi-asserted-by":"crossref","unstructured":"Davidson SM, Vander Heiden MG. Critical functions of the lysosome in Cancer biology. Annu Rev Pharmacol Toxicol. 2017 [cited 2024 Jun 11];57:481\u2013507. Available from: www.annualreviews.org.","DOI":"10.1146\/annurev-pharmtox-010715-103101"},{"key":"1837_CR12","doi-asserted-by":"crossref","unstructured":"Ellegaard AM, Bach P, J\u00e4\u00e4ttel\u00e4 M. Targeting Cancer lysosomes with good old cationic amphiphilic drugs. Reviews of physiology, biochemistry and Pharmacology. Springer Science and Business Media Deutschland GmbH 2023;107\u201352.","DOI":"10.1007\/112_2020_56"},{"issue":"1\u20133","key":"1837_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0014-5793(04)00033-X","volume":"559","author":"M K\u00f6lzer","year":"2004","unstructured":"K\u00f6lzer M, Werth N, Sandhoff K. Interactions of acid Sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant Desipramine. FEBS Lett. 2004;559(1\u20133):96\u20138.","journal-title":"FEBS Lett"},{"key":"1837_CR14","doi-asserted-by":"crossref","unstructured":"Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative Modeling of Selective Lysosomal Targeting for Drug Design. 2008.","DOI":"10.1007\/s00249-008-0338-4"},{"key":"1837_CR15","doi-asserted-by":"crossref","unstructured":"Ostenfeld MS, Fehrenbacher N, H\u00f8yer-Hansen M, Thomsen C, Farkas T, J\u00e4\u00e4ttel\u00e4 M. Effective Tumor Cell Death by S-2 Receptor Ligand Siramesine Involves Lysosomal Leakage and Oxidative Stress. 2005 [cited 2024 Jun 12]; Available from: http:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/19\/8975\/2534196\/8975-8983.pdf","DOI":"10.1158\/0008-5472.CAN-05-0269"},{"key":"1837_CR16","doi-asserted-by":"crossref","unstructured":"Ellegaard AM, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J et al. Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance. 2013 [cited 2024 Jun 12]; Available from: http:\/\/aacrjournals.org\/mct\/article-pdf\/12\/10\/2018\/2325472\/2018.pdf","DOI":"10.1158\/1535-7163.MCT-13-0084"},{"key":"1837_CR17","doi-asserted-by":"crossref","unstructured":"Ellegaard AM, Dehlendorff C, Vind AC, Anand A, Cederkvist L, Petersen NHT et al. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment. EBIOM. 2016 [cited 2024 Jun 12];9:130\u20139. Available from: http:\/\/creativecommons.org\/licenses\/by\/4.0\/","DOI":"10.1016\/j.ebiom.2016.06.013"},{"issue":"SUPPL 89","key":"1837_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1398-9995.2008.01897.x","volume":"63","author":"J Sastre","year":"2008","unstructured":"Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy: Eur J Allergy Clin Immunol. 2008;63(SUPPL 89):1\u201320.","journal-title":"Allergy: Eur J Allergy Clin Immunol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01837-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01837-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01837-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:38:20Z","timestamp":1751596700000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01837-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01837-0","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines and approved by the Regional Committee on Health Research Ethics (H-19087607) and the Danish Medicines Agency (DMA) (EudraCT number 2019-004259-35). Informed consent will be obtained prior to any study-related procedures to ensure the protection of participants\u2019 rights and confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Competing interestsThe authors declare no competing interests. HP has received funding for research purposes from Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}